enoblituzumab   Click here for help

GtoPdb Ligand ID: 9589

Synonyms: MGA-271 | MGA271
Immunopharmacology Ligand
Compound class: Antibody
Comment: Enoblituzumab (MGA271) is a humanized IgG1κ mAb with enhanced ADCC. Its target is the B7-H3 (CD276) member of the B7 family of immune regulators [2]. It has been engineered to enhance effector-mediated antitumor function via increased affinity for the activating receptor CD16A (FcγRIII) and decreased binding to the inhibitory receptor CD32B (FcγRIIB).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST sequence analysis identifies exact matches with antibody peptides claimed in patent US8802091, and specifically with a construct designated as hBRCA84D-2 [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Enoblituzumab (MGA271) is an oncology clinical candidate. It is being evaluated as a monotherapy and in combination with existing immune checkpoint inhibitor mAbs (ipilimumab, anti-CTLA4; pembrolizumab, anti-PD-1) in various Phase 1 clinical trials for a number of advanced solid tumours. Click here to link to a list of MGA271 trials registered at ClinicalTrials.gov.